ASCO Review: Progress Is Where You Find It

In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.

Without a definitive new drug ready to change practice, many observers rejected this year’s American Society of Clinical Oncology as slow.

But coming out of the meeting, the trends highlighted show a remarkable amount of progress and the tremendous efforts underway...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

17 Jun 2025

• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

16 Jun 2025

• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

06 Jun 2025

• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

06 Jun 2025

• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?